Madison Avenue Partners
Latest statistics and disclosures from Madison Avenue Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SN, GHC, TBPH, STGW, IART, and represent 71.42% of Madison Avenue Partners's stock portfolio.
- Added to shares of these 7 stocks: HES (+$43M), VSTS (+$26M), Mirati Therapeutics (+$25M), IART, TSVT, CEE, INDV.
- Started 2 new stock positions in Mirati Therapeutics, HES.
- Reduced shares in these 9 stocks: SN (-$124M), GIII (-$63M), PFSweb (-$20M), , ONL, RNAC, GOSS, LNSR, Safeguard Scientifics.
- Sold out of its positions in LNSR, MBI, PFSweb.
- Madison Avenue Partners was a net seller of stock by $-118M.
- Madison Avenue Partners has $708M in assets under management (AUM), dropping by 0.50%.
- Central Index Key (CIK): 0001801265
Tip: Access up to 7 years of quarterly data
Positions held by Madison Avenue Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Madison Avenue Partners
Madison Avenue Partners holds 19 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Sharkninja Com Shs (SN) | 26.6 | $188M | -39% | 3.7M | 51.17 |
|
| Graham Hldgs Com Cl B (GHC) | 20.6 | $146M | 209k | 696.52 |
|
|
| Theravance Biopharma (TBPH) | 11.1 | $79M | 7.0M | 11.24 |
|
|
| Stagwell Com Cl A (STGW) | 6.7 | $47M | 7.1M | 6.63 |
|
|
| Integra Lifesciences Hlds C Com New (IART) | 6.4 | $45M | +8% | 1.0M | 43.55 |
|
| G-III Apparel (GIII) | 6.3 | $45M | -58% | 1.3M | 33.98 |
|
| Hess (HES) | 6.1 | $43M | NEW | 300k | 144.16 |
|
| Vestis Corporation Com Shs (VSTS) | 4.0 | $29M | +1124% | 1.3M | 21.14 |
|
| Mirati Therapeutics | 3.5 | $25M | NEW | 417k | 58.75 |
|
| Orion Office Reit Inc-w/i (ONL) | 2.4 | $17M | -14% | 3.0M | 5.72 |
|
| Ovid Therapeutics (OVID) | 1.7 | $12M | 3.6M | 3.22 |
|
|
| Franklin Street Properties (FSP) | 1.2 | $8.4M | 3.3M | 2.56 |
|
|
| 2seventy Bio Common Stock (TSVT) | 1.1 | $7.5M | +17% | 1.8M | 4.27 |
|
| Merrimack Pharmaceuticals Com New (MACK) | 1.0 | $7.4M | 553k | 13.41 |
|
|
| Gossamer Bio (GOSS) | 0.7 | $4.6M | -17% | 5.1M | 0.91 |
|
| Central Europe and Russia Fund (CEE) | 0.4 | $2.7M | +29% | 274k | 9.75 |
|
| Indivior Ord (INDV) | 0.2 | $1.1M | +84% | 72k | 15.27 |
|
| Selecta Biosciences (RNAC) | 0.1 | $402k | -85% | 583k | 0.69 |
|
| Safeguard Scientifics Com New | 0.0 | $207k | -26% | 264k | 0.78 |
|
Past Filings by Madison Avenue Partners
SEC 13F filings are viewable for Madison Avenue Partners going back to 2019
- Madison Avenue Partners 2023 Q4 filed Feb. 16, 2024
- Madison Avenue Partners 2023 Q3 filed Nov. 14, 2023
- Madison Avenue Partners 2023 Q2 filed Aug. 14, 2023
- Madison Avenue Partners 2023 Q1 filed May 15, 2023
- Madison Avenue Partners 2022 Q4 filed Feb. 14, 2023
- Madison Avenue Partners 2022 Q3 filed Nov. 14, 2022
- Madison Avenue Partners 2022 Q2 filed Aug. 15, 2022
- Madison Avenue Partners 2022 Q1 filed May 16, 2022
- Madison Avenue Partners 2021 Q4 filed Feb. 14, 2022
- Madison Avenue Partners 2021 Q3 filed Nov. 15, 2021
- Madison Avenue Partners 2021 Q2 filed Aug. 16, 2021
- Madison Avenue Partners 2021 Q1 filed May 17, 2021
- Madison Avenue Partners 2020 Q4 filed Feb. 12, 2021
- Madison Avenue Partners 2020 Q3 filed Nov. 16, 2020
- Madison Avenue Partners 2020 Q2 filed Aug. 14, 2020
- Madison Avenue Partners 2020 Q1 restated filed May 22, 2020